Concretely: ALT · AST · survodutide.
Both of these get recommended confidently by different people, which suggests neither is obviously right.
My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.
Under what conditions does the answer flip?
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Research-use compounds are not approved for human use, and no panel makes that safer.
Decide the action for each result before you order the test.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
The short version: a small, well-chosen panel with a baseline beats a large one without.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Worth being precise here: delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Keep the full report, not the number. You will need the units and the interval later.
Worth being precise here: this is answerable, and the answer is mostly about which tests rather than how many.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
edited 5 Feb 2025 by Dr_Ravi_Selvarajah — reworded for clarity after a comment
Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 20 Feb 2025 by Dr_Signe_Baldursdottir — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.